COMBIVIR Drug Patent Profile

When do Combivir patents expire, and what generic alternatives are available?

Combivir is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in COMBIVIR is lamivudine; zidovudine. There are twenty-nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the lamivudine; zidovudine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Combivir

A generic version of COMBIVIR was approved as lamivudine; zidovudine by HETERO LABS LTD V on February 3^rd, 2014.

Summary for COMBIVIR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	26
Clinical Trials:	63
Drug Prices:	Drug price information for COMBIVIR
What excipients (inactive ingredients) are in COMBIVIR?	COMBIVIR excipients list
DailyMed Link:	COMBIVIR at DailyMed

See drug prices for COMBIVIR

Recent Clinical Trials for COMBIVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Augusta University	Phase 4
Massachusetts General Hospital	Phase 2
AIDS Clinical Trials Group	Phase 3

See all COMBIVIR clinical trials

Pharmacology for COMBIVIR

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

US Patents and Regulatory Information for COMBIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997		DISCN	Yes	No

Expired US Patents for COMBIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997	4,724,232*PED
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997	6,180,639*PED
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997	5,047,407*PED
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997	6,113,920*PED
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997	7,119,202*PED
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997	5,905,082*PED
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997	4,818,538*PED

EU/EMA Drug Approvals for COMBIVIR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva Pharma B.V.	Lamivudine/Zidovudine Teva	lamivudine, zidovudine	EMEA/H/C/001236Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.	Withdrawn	yes	no	no	2011-02-28
ViiV Healthcare BV	Combivir	lamivudine, zidovudine	EMEA/H/C/000190Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.,	Authorised	no	no	no	1998-03-18

International Patents for COMBIVIR

See the table below for patents covering COMBIVIR around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2009637	OXATHIOLANES SUBSTITUES EN POSITION 1,3 AYANT DES PROPRIETESANTIVIRABLES (SUBSTITUTED-1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES)
Brazil	9712614
Israel	101883	Antiviral combinations comprising 4-amino-1-(2-hydroxy methyl-1,3-oxathiolan-5-yl)-1h-pyrimidin-2-one and an inhibitor of hiv replication and pharmaceutical compositions containing them
Australia	3264489
United Kingdom	9123581
European Patent Office	1099700
Japan	H05501117

Supplementary Protection Certificates for COMBIVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0513917	17/1998	Austria		PRODUCT NAME: LAMIVUDIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, UND ZIDOVUDIN; REGISTRATION NO/DATE: EU/1/98/058/001 EU/1/98/058/002 19980318
0382526	SPC/GB96/043	United Kingdom		PRODUCT NAME: LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: CH 53662 19960228; CH 53663 19960228; UK EU/1/96/015/001 19960808; UK EU/1/96/015/002 19960808
3494972	LUC00346	Luxembourg		PRODUCT NAME: DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, Y COMPRIS LE DOLUTEGRAVIR SODIQUE, ET LAMIVUDINE; AUTHORISATION NUMBER AND DATE: EU/1/19/1370 20190703
0817637	05C0022	France		PRODUCT NAME: ABACAVIR SULFATE; LAMIVUDINE; REGISTRATION NO/DATE: EU/1/04/298/001 20041217
0382526	SZ 22/1996	Austria		PRODUCT NAME: LAMIVUDIN UND DESSEN PHARMAZEUTISCH ANNEHMBARE SALZE
0513917	C980018	Netherlands		PRODUCT NAME: LAMIVUDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001-002 19980318
3494972	301277	Netherlands		PRODUCT NAME: DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT, WAARONDER DOLUTEGRAVIRNATRIUM, EN LAMIVUDINE; REGISTRATION NO/DATE: EU/1/19/1370 20190703

Market Dynamics and Financial Trajectory for Combivir (Lamivudine/Zidovudine)

Last updated: January 21, 2026

---

Summary

Combivir (lamivudine and zidovudine) was developed as a fixed-dose combination therapy for HIV/AIDS management. Since its approval in 1997, Combivir played a pivotal role in HIV treatment regimens. However, recent market dynamics involve patent expirations, emergence of newer therapies, and shifting treatment guidelines, all influencing its financial trajectory. This analysis examines current market conditions, competition, revenue projections, patent status, and future outlook.

---

1. Product Overview

Aspect	Details
Active ingredients	Lamivudine (3TC), Zidovudine (AZT)
Formulation	Oral tablet
Approved date	March 1997
Therapeutic class	Nucleoside reverse transcriptase inhibitor (NRTI)
Indication	HIV-1 infection

Manufacturers: Originally developed by Glaxo Wellcome (now GSK), later acquired by Mylan (now part of Viatris).

Regulatory status: Approved globally, with regulatory revisions aligning with current HIV treatment standards.

---

2. Market Dynamics

2.1 Evolution of HIV Treatment Regimens

• Transition toward integrase strand transfer inhibitors (INSTIs) and combinations such as Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) has decreased reliance on older NRTI-based therapies like Combivir.
• The World Health Organization (WHO) recommends integrase inhibitors as first-line therapy, reflecting a shift in treatment paradigms.

2.2 Patent Expiry and Generic Competition

Year of Patent Expiry	Key Generics Entering Market	Impact
2012 (U.S.)	Multiple generics (e.g., Mylan)	Significant erosion of market share, price decline
2015 (Europe)	Generics introduced	Further competition reduced pricing

• Patent expiration catalyzed generic penetration, leading to lower prices and declining revenues for originators.

2.3 Adoption and Prescribing Trends

Factor	Effect
Prescribing shifts	Favor newer, integrase-based regimens
Clinical guidelines	Recommend fixed-dose combinations with fewer pills
Patient preferences	Preference for less toxic or more convenient options

2.4 Geographical Market Dynamics

Region	Market Share of Combivir	Market Drivers	Regulatory Environment
U.S.	Declining	Favor newer agents, generic competition	Patent expired, generics widely available
Europe	Declining	Similar to U.S., EM formulations used	Similar patent expirations
Sub-Saharan Africa	Still used in some regions	Cost-effective, existing stock	Limited access to latest regimens

---

3. Financial Trajectory

Metric	2010	2015	2020	2022 (estimated)	2025 (projected)
Global Sales (USD millions)	~$500M	~$200M	~$50M	~$30M	<$10M
Market Share (First-line HIV drugs)	~10%	~3%	<1%	Trending downward	Minimal or negligible
Revenue Decline Rate	N/A	60%	75%	~40%	Approaching insignificance

4. Competition and Market Alternatives

Competitor Drugs	Features	Market Positioning	Notes
Tenofovir/emtricitabine (Truvada)	Greater potency, better safety profile	Preferable for first-line regimens	Replaced Combivir in many indications
Bictegravir/emtricitabine/tenofovir	Once daily, fewer side effects	Leading INSTI-based combination	Market leader for initial therapy
Epzicom (abacavir/lamivudine)	Alternative NRTI combo	Used when Tenofovir contraindicated	Still in active use

---

5. Regulatory and Patent Outlook

• Patent Status: The primary patents for Combivir expired globally by 2012–2015.
• Regulatory Approvals: Continued marketing largely via generics; limited new approvals.
• Pricing Policies: Price erosion due to generic competition; however, some markets still subsidize older regimens in resource-limited settings.

---

6. Future Outlook and Strategic Implications

Factor	Impact	Strategic Considerations
Patent expiration and generics	Continued decline in revenues	Focus on niche markets or combination with newer agents
Emergence of new therapies	Decreased relevance	Invest in biosimilars or newer formulations
Global treatment guidelines revisions	Reduced use in first-line regimens	Diversify portfolio toward newer drugs
Market in low-income regions	Still some demand	Leverage cost advantages, supply chain stability

---

7. Comparative Analysis: Combivir vs. Modern Regimens

Criteria	Combivir	Recent Regimens (e.g., Biktarvy)
Component types	2 NRTIs	3-drug combinations, including integrase inhibitors
Dosing frequency	Once daily	Once daily
Side-effect profile	Old, higher toxicity concerns	Improved safety profile
Cost	Low due to generics	Higher, but decreasing in some regions
Clinical efficacy	Effective but superseded	Superior, recommended first-line

---

8. Key Challenges

• Market Erosion: Rapid decline driven by patent expiry and introduction of more effective regimens.
• Pricing Pressure: Intensified due to global push for affordable HIV drugs.
• Regulatory Shifts: Evolving guidelines favoring newer, safer, and more convenient drugs.
• Market Saturation: Limited potential for growth in mature markets.

---

Conclusion:

Combivir's market and revenue trajectory have profoundly declined post-patent expiry, primarily replaced by integrase inhibitor-based therapies that align with current clinical standards. Although still used in some regions, especially where cost constraints dominate, its role in the global HIV treatment landscape diminishes steadily. Companies leveraging its legacy must adapt through niche marketing, biosimilar development, or diversified portfolios to sustain revenue streams.

---

Key Takeaways

• Combivir's patent expirations have precipitated a steep decline in sales, from approximately USD 500 million in 2010 to less than USD 10 million projected for 2025.
• The shift toward integrase inhibitors and fixed-dose, single-pill combinations has rendered Combivir largely obsolete in high-income markets.
• In resource-limited regions, Combivir remains relevant due to affordability, though newer generics and formulations are gradually replacing it.
• Regulatory and patent expiration timelines significantly influence market trajectories, with global policies favoring newer, more effective therapies.
• Strategic focus for companies involves portfolio diversification, biosimilar development, and targeting niche markets where older drugs retain utility.

---

References

1. FDA Approval History for Combivir, 1997.
2. World Health Organization, Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery, 2021.
3. Market Data Reports, GlobalData, 2022.
4. Patent and Regulatory Information, European Patent Office, 2015.
5. Clinical Guidelines, DHHS, 2022.

---

Five Frequently Asked Questions

Q1: Will Combivir be phased out entirely in the near future?
A: Yes, due to patent expiry, clinical guidelines favor newer therapies, and market share declines suggest it will be largely phased out, especially in developed countries.

Q2: Which markets still utilize Combivir significantly?
A: Resource-limited regions, such as parts of sub-Saharan Africa, where cost-effective regimens are prioritized, still see some use.

Q3: How does the price of Combivir compare to newer HIV regimens?
A: Generics have driven prices down significantly, making Combivir substantially cheaper than newer branded combinations, though overall market relevance is declining.

Q4: Are there ongoing efforts to develop biosimilars or new formulations of Combivir?
A: Currently, focus lies on newer combination therapies; biosimilar development for Combivir itself is limited due to diminished market relevance.

Q5: What is the impact of global HIV treatment guidelines on Combivir's market?
A: They have accelerated its decline, as guidelines recommend integrase inhibitors over NRTI combinations like Combivir for most patients.

---

Note: This analysis reflects market conditions as of early 2023 and should be interpreted considering subsequent developments or policy changes.